Application of macrophage subset and regulator thereof in acute graft versus host disease (aGVHD)

A graft-versus-host, macrophage technology, applied in the field of biomedicine

CN112675201AActive Publication Date: 2021-04-20PEOPLES HOSPITAL PEKING UNIV
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-04-20

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of a macrophage subset and a regulator thereof in acute graft versus host disease (aGVHD). The application of the substance for detecting the expression quantity of a KLF4 transcription factor or a coded nucleic acid of the KLF4 transcription factor in the macrophage comprises the following steps: preparing a product for detecting the polarization / functional state of the macrophage of an aGVHD patient, diagnosing the aGVHD and / or detecting whether M1 / M2 polarization imbalance occurs in the macrophage or not. It is found that significant decrease of the KLF4 in macrophages is a biomarker of M1 / M2 polarization imbalance function change. The macrophage subset and regulator thereof can be used for detecting the polarization and functional state of the macrophage of the aGVHD patient after hematopoietic stem cell transplantation, and has important clinical significance for disease layered diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The present invention relates to the field of biomedical, and more particularly to macrophage subsets and its modulators in an acute transplantive anti-host disease.Background technique

[0002] Acute transplantive anti-host disease (AGVHD) is still an important comment of alone hematopoietic stem cell transplantation. AgvHD is often considered immunized by immune-mediated diseases. Specifically, T lymphocytes in the foreign donor grafts, a series of "cytokines storm" motivations launched, greatly enhanced their antigen against the subject The immune response is based on the subject target cells to launch cytotoxic attacks, of which the skin, liver and intestines are the main target objectives, resulting in increased patient-related mortality and increase in medical expenses. Glucocorticoids are current AGVHD's first-line treatment options, but still 40-60% of patients have hormone resistance, and existing second-line therapy effect is poor. Therefore, the in-depth ...

Examples

Embodiment 1

[0046]Example 1. Application of different macrophage subsets and its regulators in patients with acute transfer

[0047]First, experimental materials

[0048]1. Monoclonal antibody: CD68-FITC (BD Biosciences), CCR2-Alexa Fluor 647 (BDBISCIENCES), CX3CR1-PERCP / CY5.5 (BioLegend), CD163-PE / CY7 (Biolegend), CD14-PEgend CD16-APC / CY7 (BioLegend), IL-6-APC (BD Bioscience), TGF-β-BV421 (BDBiosciences), TNF-ɑ-BV650 (BD Biosciences). CD3-APC / H7 (BD Biosciences), CD8-BV510 (BioLegend), CD25-PE / CY7 (Biolegend), IFN-γ-PERCP / CY5.5 (BioLegend), IL-4-PE (BDBiosciences), IL17A- Fitc (BD Biosciences), Foxp3-Eflour660 (eBioscience).

[0049]2. DAPI solution: Item No. C0065, Beijing So Laobao Company.

[0050]3. Diecetylated low density lipoprotein: DII-ACLDL, Life Technologies.

[0051]4. Balb / c mice in rat BALB / C, Range C57BL / 6 mice (Beijing Virong Lihua Experimental Animal Technology Co., Ltd.).

[0052]5. Recombinant people M-CSF: Catalog # 300-25, US Peprotech.

[0053]6. People CD14 Sorted Magnetic ...